[1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10-30.10.3322/canjclin.55.1.1015661684]Search in Google Scholar
[2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592.10.1093/annonc/mdl49817287242]Search in Google Scholar
[3. Frank C Detterbeck, Sandra Zelman Lewis, Rebecca Diekemper, Doreen Addrizzo Harris, Michael Alberts. Diagnosis and Management of lung Cancer, 3rd ed. American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5_suppl):7S-37S.10.1378/chest.12-237723649434]Search in Google Scholar
[4. Howard BA, Furumai R, Campa MJ, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 2005;65:8853–8860.10.1158/0008-5472.CAN-05-121916204056]Search in Google Scholar
[5. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.10.1056/NEJMoa06188417167137]Search in Google Scholar
[6. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 2008;68:183–196.10.1016/j.critrevonc.2008.05.00218606548]Search in Google Scholar
[7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182—1186.10.1056/NEJM1971111828521084938153]Search in Google Scholar
[8. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;41:143-158.10.1016/j.lungcan.2005.09.00516360975]Search in Google Scholar
[9. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphaticmetastasis. J ExpMed. 2005;201:1089–1099.10.1084/jem.20041896221313215809353]Search in Google Scholar
[10. Kawai H, Minamiya Y, Ito M, et al. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer 2008;59:41–47.10.1016/j.lungcan.2007.08.00117868952]Search in Google Scholar
[11. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19:5598–5605.10.1038/sj.onc.1203855]Search in Google Scholar
[12. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000;82:1427—1432.10.1054/bjoc.1999.1129]Search in Google Scholar
[13. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Invading edge vs. inner (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol. 2000;192:140—149.10.1002/1096-9896(2000)9999:9999<::AID-PATH693>3.0.CO;2-R]Search in Google Scholar
[14. Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and VEGFR-3mRNA is a predictor of lymph nodemetastasis in non-small cell lung cancer. Br J Cancer. 2006;95:75–79.10.1038/sj.bjc.6603209]Search in Google Scholar
[15. Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001;33(2–3):171–179.10.1016/S0169-5002(01)00200-8]Search in Google Scholar
[16. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3(6):861–865.]Search in Google Scholar
[17. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851—858.10.1016/0006-291X(89)92678-8]Search in Google Scholar
[18. De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989—991.10.1126/science.1312256]Search in Google Scholar
[19. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835—846.10.1016/0092-8674(93)90573-9]Search in Google Scholar
[20. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 2006;94:1355–1360.10.1038/sj.bjc.6603120]Search in Google Scholar
[21. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol. 2006;209:34—43.10.1002/path.1943]Search in Google Scholar
[22. Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol. 2006;18:151–155.10.1097/01.cco.0000208788.99570.0e]Search in Google Scholar
[23. Seto T, HigashiyamaM, Funai H, Imamura F, Uematsu K, Seki N, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53:91–96.10.1016/j.lungcan.2006.02.009]Search in Google Scholar
[24. Decaussin M, Sartelet H, Robert C, MoroD, Claraz C, Brambilla C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGFR1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188:369–377.10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X]Search in Google Scholar
[25. Wang S, Liu H, Ren L, Pan Y, Zhang Y. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia. 2008; 10:399–407.10.1593/neo.07613]Search in Google Scholar
[26. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003;63:4801–4804.]Search in Google Scholar
[27. Feng Y, Hu J, Ma J, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways, Eur J Cancer. 2011;47:2353-2363.]Search in Google Scholar
[28. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996;73:931–934.10.1038/bjc.1996.166]Search in Google Scholar
[29. Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer, Clinical Reviews in Oncology/Hematology. 2012,84:149-160.10.1016/j.critrevonc.2012.02.012]Search in Google Scholar
[30. Kadota K, Huang CL, Liu D, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–1067.10.1016/j.ejca.2008.03.012]Search in Google Scholar
[31. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125–132.10.1016/S0169-5002(01)00195-7]Search in Google Scholar
[32. Pajares MJ, Agorreta J, Larrayoz M, et al. Expression of tumorderived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012;30:1129–1136.10.1200/JCO.2011.37.4231]Search in Google Scholar
[33. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir. 2002;19:577–584.]Search in Google Scholar
[34. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4:1094–1103.10.1097/JTO.0b013e3181a97e31]Search in Google Scholar
[35. Nakashima T, Huang CL, Liu D, Kameyama K, Masuya D, Ueno M, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit.2004;10:BR157–165.]Search in Google Scholar
[36. Dziadziuszko R, Chyczewski L, Jassem E, Jassem J. Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)—a preliminary report. Folia HistochemCytobiol. 2001;39(Suppl. 2):100–101.]Search in Google Scholar
[37. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296:1883–1886.10.1126/science.1071420]Search in Google Scholar
[38. Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Munoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 2009;115:1701–171210.1002/cncr.24193]Search in Google Scholar
[39. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal. 2000;12:123–133.10.1016/S0898-6568(99)00076-5]Search in Google Scholar
[40. Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008;68:7828–7837.10.1158/0008-5472.CAN-08-1488]Search in Google Scholar
[41. Donnem T, Al-Shibli K, Al-Saad C, Delghandi MP, Busund LT, Bremnes RM. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells, Lung Cancer. 2009;63:277-283.]Search in Google Scholar
[42. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Tastepe I. Vascular Endothelial Growth Factor Immunostaining Correlates with Postoperative elapse and Survival in Non-Small Cell Lung Cancer, Arch Res med. 2007;38:764-768.]Search in Google Scholar
[43. Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997;74:64–68.10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I]Search in Google Scholar
[44. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg. 1998;115:1007–1014.10.1016/S0022-5223(98)70398-8]Search in Google Scholar
[45. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer. 2005;115:545–555.10.1002/ijc.20898]Search in Google Scholar
[46. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–623.10.1093/clinchem/47.4.617]Search in Google Scholar
[47. Bonnesen B, Pappot H, Holmstav J, Guldhammer Skov B. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis, Lung Cancer. 2009,66:314-318.10.1016/j.lungcan.2009.02.013]Search in Google Scholar
[48. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33(2–3):125–132.10.1016/S0169-5002(01)00195-7]Search in Google Scholar
[49. Hormbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis. 2002;19:651–663.]Search in Google Scholar
[50. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond). 1998;94:395–404.10.1042/cs0940395]Search in Google Scholar
[51. Sorreensen S, Fohlin H, Lindgren A, et al. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy, Eur J Cancer. 2013;49:115-120.]Search in Google Scholar
[52. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer. 2009;9:421.10.1186/1471-2407-9-421]Search in Google Scholar
[53. Ohta Y, Watanabe Y, Murakami S, et al. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer. 1997;76(8):1041–1045.10.1038/bjc.1997.505]Search in Google Scholar
[54. Brattstrom D, Bergqvist M, Hesselius P, et al. Elevatedpreoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer. 2002;37(1):57–63.10.1016/S0169-5002(02)00027-2]Search in Google Scholar
[55. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–187.10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7]Search in Google Scholar
[56. Lin-Hsu I., Wu-Chou S., Jing-Jou Y., Jia-Ming C., Wu-Wei L. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371-376.10.1016/j.lungcan.2008.12.007]Search in Google Scholar
[57. Grove CS, Lee YC. Vascular endothelial growth factor: the keymediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8:294–301.10.1097/00063198-200207000-00009]Search in Google Scholar
[58. Nathanson SD. Insights into the mechanisms of lymph node metastases. Cancer. 2003;98:413—423.10.1002/cncr.11464]Search in Google Scholar
[59. Cao Y. Emerging mechanisms of tumor lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005;5:1—9.10.1038/nrc1693]Search in Google Scholar
[60. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastases. Nat Rev Cancer. 2002;2:573—583.10.1038/nrc863]Search in Google Scholar
[61. Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, et al. Enhancement of pleural dissemination and lymph node metastases of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45:325—337.10.1016/j.lungcan.2004.02.02115301873]Search in Google Scholar
[62. Saintigny P., Kambouchner M., Li M., et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: Concurrent expression in cancer cells from primary tumour and metastatic lymph node, Lung Cancer. 2007;58:205-213.]Search in Google Scholar
[63. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65:4739-4746.10.1158/0008-5472.CAN-04-457615930292]Search in Google Scholar
[64. Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, Alitalo K, et al. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors. 2002;20:99-107.10.1080/0897719029003196912148568]Search in Google Scholar
[65. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–436.10.1038/nrc136915170445]Search in Google Scholar
[66. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191.10.1200/JCO.2004.11.02215169807]Search in Google Scholar
[67. Reck M, Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer, Lung Cancer. 2009;63:1-9.]Search in Google Scholar
[68. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.2.2008. Available at: http://www.nccn.org/professionals/physiciangls/PDF/nscl.pdf.]Search in Google Scholar